News

The Food, Drug and Cosmetic Act (FDCA) gives the U.S. Food and Drug Administration (FDA) the authority to ensure that drug/device promotion is not false and/or misleading. But does that mean the FDA can regulate physician comments on drugs and devices? Dr. Goldberg provides his insight in this month's Legal Eagle column.

This article is the first of our series on psychodermatology from Gina M. Caputo, D.O. In it, she highlights the prevalence of emotional disorders in patients with skin diseases, and introduces the four main classifications of psychodermatological disorders.

What does that mean for providers who offer the body contouring and muscle defining technology? Experts weigh in.

New drugs in clinical trials for the treatment of warts and molluscum contagiosum could improve on currently available therapies, which are limited, used off-label and often cause tissue damage.

Technology keeping you tethered to work? It’s time to unplug.

Although skin aging is largely a result of genetics and UV exposure, menopause also plays a significant role.

In this pipeline report, Dermatology Times presents insights into Hh pathway inhibitors currently in phase 2 and phase 3 for the treatment of basal cell carcinoma. 

‘Inflammaging’ is real, says one expert, and can result from chronic inflammation, cell senescence and other internal processes.

Study authors describe results of a surgical technique used to remove permanent lip fillers.

CBD oil may offer a spectrum of health benefits, including the treatment of skin disorders, but experts say claims are more anecdotal than scientific.

Crown Laboratories, long anchored by its Blue Lizard Australian Sunscreen business, recently added the Vita Liberata beauty and Bellus Medical aesthetics divisions to their portfolios.

Animal study suggests age may be a factor in fat graft volume retention.

In this follow up to last month’s Innovations column on intellectual property and technology transfer, Raymond A. Miller, J.D., and Steve Xu, M.D., FAAD discuss how to utilize patents to maximize value for your venture.

David J. Goldberg, M.D., J.D., discusses the Family and Medical Leave Act (FMLA) and what you should know to protect yourself and your practice.

Earlier this year, Galderma announced a new multi-disciplinary group of advisory members that compose The Women in Aesthetics Leadership Council. In this article, Dermatology Times acknowledges and congratulates the women on the advisory board who fall under the dermatology specialty.

Cognitive behavioral therapy (CBT) can successfully treat the physical symptoms of psoriasis and systemic treatment doesn't seem to provide an extra boost to its effectiveness, a new systematic review and meta-analysis finds.

Some might view the use of non-human intelligence in dermatology as a threat. But this expert believes it's up to dermatologists to transform this technology into an opportunity to ‘augment' clinical practice.

In this month's Innovations column, Steve Xu, M.D., FAAD, begins the first part of a two-part mini-series discussing what innovators should know about intellectual property. This installment focuses on the different scenarios innovators may run into when dealing with the transfer of technological property, called technology transfer.

DAXI clinical trials suggest duration as differentiator with Revance’s proprietary peptide technology.

Medications to treat acne take time to work and might not clear acne completely. To enhance outcomes from acne medications, this expert uses energy-based devices.

Laser-based procedure for autologous fat transfer may increase fat survival.

It is common knowledge that both not-for-profit and for-profit hospitals across the U.S. have policies of charging uninsured patients more. And some physicians have done the same. But patients are starting to question these policies, landing some hospitals and physicians in hot water.

Caregivers of children with autism often expect dermatologists to have an understanding of the disorder, but that may not always be the case. Learn how to best navigate clinical situations with this patient population in this article.

Despite evidence that topical cannabinoids may relieve symptoms, more research is needed.